Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

908 Devices (MASS) stock in plain English

Free brief · no signupStart here
MASSPublished Nov 18, 2026
908 Devices Inc
Healthcare · Medical Devices
Manufactures portable mass spectrometry devices for chemical detection and bioprocessing analysis.
Assets:
Boston headquartersHouses primary assembly and engineering teams in Massachusetts
MX908 platformSupplies handheld trace chemical detectors for first responders
Rebel analyzersMonitors cell culture media for biopharmaceutical drug development
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

69
OPS ScoreOperating finances
Latest quote
-1.58%$9.37
$389.62M
n/a (loss)
$65.81M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 18, 2026Quotes updated Nov 20, 04:00 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was MASS. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does 908 Devices (MASS) do?

908 Devices Inc (MASS) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Manufactures portable mass spectrometry devices for chemical detection and bioprocessing analysis. It shrinks complex laboratory mass spectrometry equipment into handheld and benchtop devices used in the field. It is worth $389.62M on the market and sold $65.81M over the last year.

Market cap
$389.62M
P/E ratio
None (reported a loss)
Annual sales
$65.81M
Sector
Healthcare
Industry
Medical Devices
Brief updated
Nov 18, 2026

Brands and businesses behind MASS

  • MX908: A handheld mass spectrometer that generates revenue through device sales and consumable swab kits for field chemical detection.
  • Rebel: A benchtop cell culture analyzer generating revenue via device placements and single-use microfluidic cartridges for biopharma labs.
  • ZipChip: A separation platform generating revenue through instrument sales and consumable microchip cassettes for biotherapeutic sample preparation.

MASS’s flags, in plain English

Each flag is a number from 908 Devices’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.

Stupid Cash

Can pay this year's bills 5.4 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 3% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Still Climbing

Sales up 15.9% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Burning Cash

Losing money, profit margin of -36.7%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about MASS

How big is 908 Devices?

908 Devices’ market cap is $389.62M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $65.81M: what customers paid the company over the last year, before any costs.

What is MASS’s P/E ratio?

MASS has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with MASS?

A substantial share of hardware revenue depends on unpredictable government procurement cycles and federal defense budgets. That is one risk on 908 Devices’ card. Its first risk flag is Burning Cash, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From 908 Devices’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. MASS’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card